GSEP
AZN icon

Golden State Equity Partners’s AstraZeneca AZN Stock Holding History

Golden State Equity Partners’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.37M Buy
6,938
+2,641
+61% +$509K 0.1% 221
2025
Q4 		$790K Buy
4,297
+349
+9% +$61.2K 0.13% 182
2025
Q3 		$606K Buy
3,948
+428
+12% +$64.8K 0.1% 231
2025
Q2 		$492K Buy
3,520
+292
+9% +$40.9K 0.09% 248
2025
Q1 		$474K Buy
3,228
+323
+11% +$46.7K 0.09% 252
2024
Q4 		$381K Buy
2,905
+2,287
+370% +$320K 0.07% 283
2024
Q3 		$96.2K Buy
+618
New +$99.8K 0.05% 283

Other funds holding AZN

IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VAM
Vanguard Asset Management London, Ec4n 8af $117B AUM

Golden State Equity Partners's AZN Position: Q1 2026 in Review

Golden State Equity Partners increased its AstraZeneca (AZN) stake by 61% in Q1 2026, buying an estimated $509K and bringing the position to 6,938 shares worth $1.37M. The position accounts for 0.1% of the portfolio, ranked #221.

Golden State Equity Partners first reported a position in AZN in Q3 2024 and has held it in 7 quarters since. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • Golden State Equity Partners held 6,938 shares of AstraZeneca worth $1.37M as of Q1 2026.
  • Golden State Equity Partners bought 2,641 AstraZeneca shares in Q1 2026, an estimated $509K.
  • AstraZeneca made up 0.1% of Golden State Equity Partners's portfolio in Q1 2026, its #221 holding.
  • Golden State Equity Partners first reported a position in AstraZeneca in Q3 2024 and has held it in 7 quarters since.
  • 1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Golden State Equity Partners's 13F filing for Q1 2026, filed 28 Apr 2026.